Is There a Preferred Time Interval Between Gonadotropin-releasing Hormone (GnRH) Agonist Trigger and Oocyte Retrieval in GnRH Antagonist Cycles? A Retrospective Cohort of Planned Fertility Preservation Cycles

Overview

Journal J Assist Reprod Genet

Publisher Springer

Specialties Genetics
Reproductive Medicine

Date 2024 Mar 16

PMID 38492156

Authors

Hizkiyahu Ranit

Herzberg Shmuel

Athavale Ahlad

Greenbaum Shirley

Harari Meny

Imbar Tal

Ben-Meir Assaf

Adler Lazarovits Chana

Bentov Yaakov

Esh-Broder Efrat

Hershko Klement Anat

Affiliations

Soon will be listed here.

Abstract

Background: The ideal time frame between gonadotropin-releasing hormone (GnRH) agonist (GnRHa) trigger administration and oocyte retrieval in GnRH antagonist cycles has not been well studied. Our goal was to evaluate the effect of this time interval on oocyte yield and oocyte maturation rate in GnRH antagonist cycles designated for non-medical ("planned") oocyte cryopreservation.

Methods: We conducted a retrospective cohort study including patients who underwent elective fertility preservation, using the GnRH antagonist protocol and exclusively triggered by GnRH-agonist. We focused on the effect of the trigger-to-retrieval time interval on oocyte yield and maturation rate, while also incorporating age, body mass index (BMI), anti-Müllerian hormone (AMH) levels, basal Follicle-Stimulating Hormone (FSH) levels, as well as the type and dosage of gonadotropin FSH medication.

Results: 438 cycles were included. Trigger-to-retrieval time interval ranged from 32.03 to 39.92 h. The mean oocyte yield showed no statistically significant difference when comparing retrievals < 36 h (n = 240, 11.86 ± 8.6) to those triggered at ≥ 36 h (n = 198, 12.24 ± 7.73) (P = 0.6). Upon dividing the cohort into four-time quartiles, no significant differences in the number of retrieved oocytes were observed (P = 0.54). Multivariate regression analysis failed to reveal any significant associations between the interval and the aforementioned variables.

Conclusions: The GnRHa trigger to oocyte retrieval interval range in our cohort did not significantly affect oocyte yield and maturation rate.

References

Kwan H . Reconsideration of the safety and effectiveness of human oocyte cryopreservation. Reprod Biol Endocrinol. 2023; 21(1):22. PMC: 9969709. DOI: 10.1186/s12958-023-01071-z. View

Balkenende E, Dahhan T, Beerendonk C, Fleischer K, Stoop D, Bos A . Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. Hum Reprod. 2022; 37(8):1786-1794. PMC: 9340107. DOI: 10.1093/humrep/deac145. View

Al-Inany H, Abou-Setta A, Aboulghar M . Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006; (3):CD001750. DOI: 10.1002/14651858.CD001750.pub2. View

Marklund A, Eloranta S, Wikander I, Laczna Kitlinski M, Lood M, Nedstrand E . Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. Hum Reprod. 2020; 35(4):929-938. PMC: 7192532. DOI: 10.1093/humrep/deaa029. View

DAngelo A, Panayotidis C, Amso N, Marci R, Matorras R, Onofriescu M . Recommendations for good practice in ultrasound: oocyte pick up. Hum Reprod Open. 2019; 2019(4):hoz025. PMC: 6903452. DOI: 10.1093/hropen/hoz025. View

Oktay K, Turkcuoglu I, Rodriguez-Wallberg K . GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online. 2010; 20(6):783-8. PMC: 3557820. DOI: 10.1016/j.rbmo.2010.03.004. View

Jones Jr H, Jones G, Andrews M, Acosta A, Bundren C, Garcia J . The program for in vitro fertilization at Norfolk. Fertil Steril. 1982; 38(1):14-21. View

Shen X, Long H, Guo W, Xie Y, Gao H, Zhang J . The ovulation trigger-OPU time interval of different ovarian protocols in ART: a retrospective study. Arch Gynecol Obstet. 2020; 302(2):519-527. PMC: 7321905. DOI: 10.1007/s00404-020-05568-5. View

Bakkensen J, Flannagan K, Mumford S, Hutchinson A, Cheung E, Moreno P . A SART data cost-effectiveness analysis of planned oocyte cryopreservation versus in vitro fertilization with preimplantation genetic testing for aneuploidy considering ideal family size. Fertil Steril. 2022; 118(5):875-884. PMC: 9613595. DOI: 10.1016/j.fertnstert.2022.07.022. View

10.

Lanzone A, Fulghesu A, Apa R, Caruso A, Mancuso S . LH surge induction by GnRH agonist at the time of ovulation. Gynecol Endocrinol. 1989; 3(3):213-20. DOI: 10.3109/09513598909152302. View

11.

Aizer A, Haas J, Shimon C, Konopnicki S, Barzilay E, Orvieto R . Is There Any Association Between the Number of Oocytes Retrieved, Women Age, and Embryo Development?. Reprod Sci. 2020; 28(7):1890-1900. DOI: 10.1007/s43032-020-00391-4. View

12.

Aslan K, Kasapoglu I, Cakir C, Koc M, Celenk M, Ata B . Which is more predictive ovarian sensitivity marker if there is discordance between serum anti-Müllerian hormone levels and antral follicle count? A retrospective analysis. J Obstet Gynaecol. 2022; 42(5):1461-1466. DOI: 10.1080/01443615.2021.2003309. View

13.

Wang W, Zhang X, Wang W, Liu Y, Zhao L, Xue S . The time interval between hCG priming and oocyte retrieval in ART program: a meta-analysis. J Assist Reprod Genet. 2011; 28(10):901-10. PMC: 3220445. DOI: 10.1007/s10815-011-9613-x. View

14.

. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2012; 99(1):37-43. DOI: 10.1016/j.fertnstert.2012.09.028. View

15.

. Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline. Fertil Steril. 2021; 116(1):36-47. DOI: 10.1016/j.fertnstert.2021.02.024. View

16.

Cobo A, Garcia-Velasco J, Domingo J, Pellicer A, Remohi J . Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018; 33(12):2222-2231. DOI: 10.1093/humrep/dey321. View

17.

Al-Inany H, Youssef M, Ayeleke R, Brown J, Lam W, Broekmans F . Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016; 4:CD001750. PMC: 8626739. DOI: 10.1002/14651858.CD001750.pub4. View

18.

Raziel A, Schachter M, Strassburger D, Kasterstein E, Ron-El R, Friedler S . In vivo maturation of oocytes by extending the interval between human chorionic gonadotropin administration and oocyte retrieval. Fertil Steril. 2006; 86(3):583-7. DOI: 10.1016/j.fertnstert.2006.02.091. View

19.

Bjercke S, Tanbo T, Dale P, Abyholm T . Comparison between two hCG-to-oocyte aspiration intervals on the outcome of in vitro fertilization. J Assist Reprod Genet. 2000; 17(6):319-22. PMC: 3455398. DOI: 10.1023/a:1009401027251. View

20.

Reichman D, Goldschlag D, Rosenwaks Z . Value of antimüllerian hormone as a prognostic indicator of in vitro fertilization outcome. Fertil Steril. 2014; 101(4):1012-8.e1. DOI: 10.1016/j.fertnstert.2013.12.039. View